BSX · CIK 0000885725 · operating
Boston Scientific develops and manufactures medical devices for interventional procedures across multiple therapeutic areas. The company's portfolio spans gastrointestinal treatment devices including endoscopic instruments, stent systems, and diagnostic scopes; urological products such as ureteral stents, catheters, and laser systems; and neurological devices for spinal cord stimulation, deep brain stimulation, and chronic pain management. The company also produces devices for cancer diagnosis and treatment.
The firm operates through two primary segments: MedSurg and Cardiovascular. The Cardiovascular segment encompasses implantable devices for heart rhythm management, including pacemakers and defibrillators, as well as technologies for diagnosing and treating cardiac arrhythmias, peripheral vascular disease, and structural heart conditions. This segment includes the WATCHMAN FLX left atrial appendage closure device and remote patient monitoring systems.
With approximately 59,000 full-time employees, Boston Scientific maintains significant scale across its operations. The company maintains a global footprint, developing and distributing products across multiple continents to serve the interventional medical device market. Headquarters are located in Marlborough, Massachusetts, with the company incorporated in Delaware and publicly traded on the New York Stock Exchange.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $1.94 | $1.96 | +55.2% | |
| 2024 | $1.25 | $1.26 | +16.8% | |
| 2023 | $1.07 | $1.08 | +137.8% | |
| 2022 | $0.45 | $0.45 | -34.8% | |
| 2021 | $0.69 | $0.69 | +962.5% | |
| 2020 | $-0.08 | $-0.08 | -102.4% | |
| 2019 | $3.33 | $3.38 | +179.8% | |
| 2018 | $1.19 | $1.21 | +1387.5% | |
| 2017 | $0.08 | $0.08 | -68.0% | |
| 2016 | $0.25 | $0.26 | +238.9% | |
| 2015 | $-0.18 | $-0.18 | -100.0% | |
| 2014 | $-0.09 | $-0.09 | +0.0% | |
| 2013 | $-0.09 | $-0.09 | +96.9% | |
| 2012 | $-2.89 | $-2.89 | -1096.6% | |
| 2011 | $0.29 | $0.29 | +93.3% | |
| 2010 | $0.15 | $0.16 | +122.1% | |
| 2009 | $-0.68 | $-0.68 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-17 | 0000885725-26-000010 | SEC ↗ |
| 2024-12-31 | 2025-02-18 | 0000885725-25-000011 | SEC ↗ |
| 2023-12-31 | 2024-02-20 | 0000885725-24-000017 | SEC ↗ |
| 2022-12-31 | 2023-02-23 | 0000885725-23-000008 | SEC ↗ |
| 2021-12-31 | 2022-02-23 | 0000885725-22-000006 | SEC ↗ |
| 2020-12-31 | 2021-02-23 | 0000885725-21-000008 | SEC ↗ |